Assessing CD36 and CD47 expression levels in solid tumor indications to stratify patients for VT1021 treatment

Suming Wang; Victor Zota; Melanie Y Vincent; Donna Clossey; Jian Jenny Chen; Michael Cieslewicz; Randolph S Watnick; James Mahoney; Jing Watnick

doi:10.1038/s41698-024-00774-9

Assessing CD36 and CD47 expression levels in solid tumor indications to stratify patients for VT1021 treatment

NPJ Precis Oncol. 2024 Dec 3;8(1):278. doi: 10.1038/s41698-024-00774-9.

Authors

Suming Wang¹, Victor Zota², Melanie Y Vincent², Donna Clossey², Jian Jenny Chen², Michael Cieslewicz², Randolph S Watnick³, James Mahoney², Jing Watnick⁴

Affiliations

¹ Vigeo Therapeutics, Cambridge, MA, USA. [email protected].
² Vigeo Therapeutics, Cambridge, MA, USA.
³ Boston Children's Hospital, Boston, MA, USA.
⁴ Vigeo Therapeutics, Cambridge, MA, USA. [email protected].

Abstract

Despite the development of cancer biomarkers and targeted therapies, most cancer patients do not have a specific biomarker directly associated with effective treatment options. We have developed VT1021 that induces the expression of thrombospondin-1 (TSP-1) in myeloid-derived suppressor cells (MDSCs) recruited to the tumor microenvironment (TME). Our studies identified CD36 and CD47 as dual biomarkers that can be used as patient stratifying tools and prognostic biomarkers for VT1021 treatment.